Literature DB >> 8935705

Alpha 2-autoreceptors and alpha 2-heteroreceptors modulating tyrosine and tryptophan hydroxylase activity in the rat brain in vivo: an investigation into the alpha 2-adrenoceptor subtypes.

S Esteban1, J Lladó, J A García-Sevilla.   

Abstract

The subtype determination of auto- and hetero-alpha 2-adrenoceptors modulating the synthesis of noradrenaline (NA) and serotonin (5-HT), respectively, was assessed using the accumulation of 3,4-dihydroxyphenylalanine (dopa) and 5-hydroxytryptophan (5-HTP) after decarboxylase inhibition as a measure of the rate of tyrosine and tryptophan hydroxylation in the rat brain in vivo. In the cerebral cortex and hippocampus, Org 3770 (non-selective alpha 2-adrenoceptor antagonist, 0.5-10 mg/kg, i.p.) increased (43%-58%) and clonidine (non-selective alpha 2-adrenoceptor agonist, 1 mg/kg) decreased (37%-49%) the synthesis of dopa. Also the antagonist ARC 239 (alpha 2B/C selective, 5-40 mg/kg) increased the synthesis of dopa in cortex (39%-46%) and hippocampus (17%-85%). In contrast, the antagonist BRL 44408 (alpha 2D selective, 1-10 mg/kg) did not increase the synthesis of dopa in cortex, and increased it modestly in hippocampus only. The agonist guanoxabenz (alpha 2B/C selective, 0.03-3 mg/kg) decreased the synthesis of dopa in both brain regions (20%-65%), whereas the agonist oxymetazoline (alpha 2D selective, 0.1-3 mg/kg) failed to do so. These results indicated that the alpha 2-autoreceptors that modulate the synthesis of dopa/NA are probably associated with the alpha 2B/C-subtypes. In cortex and hippocampus, clonidine decreased (35%-53%) the synthesis of 5-HTP but Org 3770 failed to induce the opposite effect (except the 2 mg/kg dose in cortex). BRL 44408 markedly increased the synthesis of 5-HTP in cortex (113%-148%) but not in hippocampus. Similarly, also ARC239 increased the formation of 5-HTP in cortex (36%-48%) but not in hippocampus, where it was decreased (30%-55%). Oxymetazoline decreased the synthesis of 5-HTP in hippocampus (28%-30%) but failed to do so in cortex. Guanoxabenz in the low dose range (0.03-0.3 mg/kg) did not decrease the synthesis of 5-HTP in any brain region. These results indicated that the alpha 2-heteroreceptors that modulate the synthesis of 5-HTP/5-HT may well be different from the proposed alpha 2B/C-autoreceptors modulating the synthesis of dopa/NA. These alpha 2-heteroreceptors appear to be associated with the alpha 2D-subtype.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8935705     DOI: 10.1007/bf00261435

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  38 in total

Review 1.  Modulation of neurotransmitter release by presynaptic autoreceptors.

Authors:  K Starke; M Göthert; H Kilbinger
Journal:  Physiol Rev       Date:  1989-07       Impact factor: 37.312

2.  Different alpha-adrenoreceptors in the central nervous system mediating biochemical and functional effects of clonidine and receptor blocking agents.

Authors:  N E Andén; M Grabowska; U Strömbom
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

3.  Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase.

Authors:  A Carlsson; J N Davis; W Kehr; M Lindqvist; C V Atack
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

4.  Are the prejunctional alpha 2-adrenoceptors of the rat vas deferens and submandibular gland of the alpha 2A- or alpha 2D-subtype?

Authors:  K Smith; J R Docherty
Journal:  Eur J Pharmacol       Date:  1992-08-25       Impact factor: 4.432

5.  Studies on the origin of rat hippocampal dihydroxyphenylacetic acid using microdialysis.

Authors:  A Vahabzadeh; M Fillenz
Journal:  Neurosci Lett       Date:  1992-02-17       Impact factor: 3.046

6.  Alpha 2-adrenoceptor modulation of 5-HT biosynthesis in the rat brain.

Authors:  M Yoshioka; M Matsumoto; H Togashi; C B Smith; H Saito
Journal:  Neurosci Lett       Date:  1992-05-11       Impact factor: 3.046

7.  Effect of clonidine on the release of serotonin from the rat hippocampus as measured by microdialysis.

Authors:  M Yoshioka; M Matsumoto; H Togashi; C B Smith; H Saito
Journal:  Neurosci Lett       Date:  1992-05-11       Impact factor: 3.046

8.  In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus.

Authors:  R Mongeau; P Blier; C de Montigny
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

9.  Alpha 2-adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo.

Authors:  R Tao; S Hjorth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

10.  Alpha 2-adrenoceptor subtypes identified by [3H]RX821002 binding in the human brain: the agonist guanoxabenz does not discriminate different forms of the predominant alpha 2A subtype.

Authors:  M Sastre; J A García-Sevilla
Journal:  J Neurochem       Date:  1994-09       Impact factor: 5.372

View more
  3 in total

1.  Brain alpha(2)-adrenoceptors in monoamine-depleted rats: increased receptor density, G coupling proteins, receptor turnover and receptor mRNA.

Authors:  C Ribas; A Miralles; X Busquets; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain.

Authors:  David Moranta; Susana Esteban; Jesús A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-16       Impact factor: 3.000

Review 3.  Therapeutic Potential of Selectively Targeting the α2C-Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective.

Authors:  Madeleine Monique Uys; Mohammed Shahid; Brian Herbert Harvey
Journal:  Front Psychiatry       Date:  2017-08-14       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.